Novo Nordisk/NVO

$121.54

-0.58%
-
1D1W1MYTD1YMAX

About Novo Nordisk

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.

Ticker

NVO

Sector

Healthcare

Trading on

NYSE

Industry

Biotechnology & Drugs

CEO

Lars Fruergaard Joergensen

Employees

63,370

Headquarters

Bagsvaerd, Denmark

Novo Nordisk Metrics

BasicAdvanced
$421B
Market cap
45.56
P/E ratio
$2.71
EPS
0.42
Beta
$1.02
Dividend rate
1.11%
Dividend yield

What the Analysts think about Novo Nordisk

Analyst Ratings

Majority rating from 7 analysts.
Buy

Price Targets

Average projection from 5 analysts.
4.4% upside
High $141.45
Low $95.98
$121.54
Current price
$126.89
Average price target

Novo Nordisk Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
33.34% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
Kr65.86B
12.14%
Net income
Kr21.96B
-2.29%
Profit margin
33.34%
-12.88%

Novo Nordisk Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 9.55%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
Kr4.39
Kr4.32
Kr5.00
Kr4.91
-
Expected
Kr4.32
Kr4.41
Kr5.00
Kr4.48
Kr5.38
Surprise
1.62%
-2.09%
0.09%
9.55%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
ADR

Upcoming events

Buy or sell Novo Nordisk stock

Buy or sell Novo Nordisk stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing